Article
EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
Oncogene - 2 Jan 2015
Li L, Puliyappadamba V T, Chakraborty S, Rehman A, Vemireddy V, Saha D, Souza R F, Hatanpaa K J, Koduru P, Burma S, Boothman D A, Habib A A
Abstract excerpt
Epidermal growth factor receptor (EGFR)vIII is the most common EGFR mutant found in glioblastoma (GBM). EGFRvIII does not bind ligand, is highly oncogenic and is usually coexpressed with EGFR wild type (EGFRwt). EGFRvIII activates Met, and Met contributes to EGFRvIII-mediated oncogenicity and resistance to treatment. Here, we report that addition of EGF results in a rapid loss of EGFRvIII-driven Met...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.